Jian Xu1, Deying Tian. 1. Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China.
Abstract
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and everolimus, are currently approved for the treatment of several malignancies. Hematological toxicities have been reported with these drugs, but overall incidence and relative risk remains undefined. We perform an up-to-date meta-analysis to determine the incidence and risk of hematologic toxicities associated with mTOR inhibitors. METHODS: Several databases were searched, including PubMed, Embase and Cochrane databases. Eligible studies included prospective phase II and III trials of temsirolimus and everolimus with adequate safety data profile reporting anemia, leucopenia, neutropenia or thrombocytopenia. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated by using either random effects or fixed effects models according to the heterogeneity of included studies. RESULTS: A total of 5436 patients with a variety of solid tumors from 26 clinical trials were included for the meta-analysis. The overall incidences of mTOR inhibitor associated all-grade and high-grade hematologic toxicities were, respectively: anemia--38.8% and 7.5%; leucopenia--19.6% and 1.8%; neutropenia--14.9% and 5.6%; thrombocytopenia--33.1% and 3.6%. Compared to placebo/control arms, mTOR inhibitors were associated with a significantly increased risk of all-grade (RR 2.05, 95% CI: 1.52-2.77; p < 0.001) and high-grade anemia (RR 1.57, 95% CI: 1.20-2.05; p = 0.001), all-grade (RR 6.03, 95% CI: 2.76-13.14; p < 0.001) and high-grade thrombocytopenia (RR 2.73, 95% CI: 1.87-3.99; p < 0.001). Additionally, a non-significantly increased risk of all-grade leucopenia (RR 1.46, 95% CI: 0.66-3.23; p = 0.34) and neutropenia (RR 1.77, 95% CI: 0.80-3.93; p = 0.16) was observed in the mTOR inhibitor group, while the risk of high-grade leucopenia (RR 0.53, 95% CI: 0.31-0.90, p = 0.019) and neutropenia (RR 0.96, 95% CI: 0.62-1.51; p = 0.87) did not increase. Similar results were also observed in sub-group analysis according to mTOR inhibitor based regimens. CONCLUSIONS: The use of mTOR inhibitors is associated with a significant increase in the risk of developing all-grade and high-grade anemia and thrombocytopenia compared with placebo/control arms.
BACKGROUND:Mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and everolimus, are currently approved for the treatment of several malignancies. Hematological toxicities have been reported with these drugs, but overall incidence and relative risk remains undefined. We perform an up-to-date meta-analysis to determine the incidence and risk of hematologic toxicities associated with mTOR inhibitors. METHODS: Several databases were searched, including PubMed, Embase and Cochrane databases. Eligible studies included prospective phase II and III trials of temsirolimus and everolimus with adequate safety data profile reporting anemia, leucopenia, neutropenia or thrombocytopenia. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated by using either random effects or fixed effects models according to the heterogeneity of included studies. RESULTS: A total of 5436 patients with a variety of solid tumors from 26 clinical trials were included for the meta-analysis. The overall incidences of mTOR inhibitor associated all-grade and high-grade hematologic toxicities were, respectively: anemia--38.8% and 7.5%; leucopenia--19.6% and 1.8%; neutropenia--14.9% and 5.6%; thrombocytopenia--33.1% and 3.6%. Compared to placebo/control arms, mTOR inhibitors were associated with a significantly increased risk of all-grade (RR 2.05, 95% CI: 1.52-2.77; p < 0.001) and high-grade anemia (RR 1.57, 95% CI: 1.20-2.05; p = 0.001), all-grade (RR 6.03, 95% CI: 2.76-13.14; p < 0.001) and high-grade thrombocytopenia (RR 2.73, 95% CI: 1.87-3.99; p < 0.001). Additionally, a non-significantly increased risk of all-grade leucopenia (RR 1.46, 95% CI: 0.66-3.23; p = 0.34) and neutropenia (RR 1.77, 95% CI: 0.80-3.93; p = 0.16) was observed in the mTOR inhibitor group, while the risk of high-grade leucopenia (RR 0.53, 95% CI: 0.31-0.90, p = 0.019) and neutropenia (RR 0.96, 95% CI: 0.62-1.51; p = 0.87) did not increase. Similar results were also observed in sub-group analysis according to mTOR inhibitor based regimens. CONCLUSIONS: The use of mTOR inhibitors is associated with a significant increase in the risk of developing all-grade and high-grade anemia and thrombocytopenia compared with placebo/control arms.
Authors: Jacky Chung; Daniel E Bauer; Alireza Ghamari; Christopher P Nizzi; Kathryn M Deck; Paul D Kingsley; Yvette Y Yien; Nicholas C Huston; Caiyong Chen; Iman J Schultz; Arthur J Dalton; Johannes G Wittig; James Palis; Stuart H Orkin; Harvey F Lodish; Richard S Eisenstein; Alan B Cantor; Barry H Paw Journal: Sci Signal Date: 2015-04-14 Impact factor: 8.192
Authors: Demetrios Kalaitzidis; Dongjun Lee; Alejo Efeyan; Youmna Kfoury; Naema Nayyar; David B Sykes; Francois E Mercier; Ani Papazian; Ninib Baryawno; Gabriel D Victora; Donna Neuberg; David M Sabatini; David T Scadden Journal: J Clin Invest Date: 2017-03-20 Impact factor: 14.808
Authors: R Ter Heine; N P van Erp; H J Guchelaar; J W de Fijter; M E J Reinders; C M van Herpen; D M Burger; D J A R Moes Journal: Br J Clin Pharmacol Date: 2018-05-06 Impact factor: 4.335
Authors: Thomas E Witzig; Craig Reeder; Jing Jing Han; Betsy LaPlant; Mary Stenson; Han W Tun; William Macon; Stephen M Ansell; Thomas M Habermann; David J Inwards; Ivana N Micallef; Patrick B Johnston; Luis F Porrata; Joseph P Colgan; Svetomir Markovic; Grzegorz S Nowakowski; Mamta Gupta Journal: Blood Date: 2015-04-28 Impact factor: 22.113
Authors: Vasilios Karavasilis; Epaminontas Samantas; Georgia-Angeliki Koliou; Anna Kalogera-Fountzila; George Pentheroudakis; Ioannis Varthalitis; Helena Linardou; Grigorios Rallis; Maria Skondra; Georgios Papadopoulos; George Papatsibas; Joseph Sgouros; Athina Goudopoulou; Konstantine T Kalogeras; Christos Dervenis; Dimitrios Pectasides; George Fountzilas Journal: Target Oncol Date: 2018-12 Impact factor: 4.493
Authors: Amy K LeBlanc; Timothy M Fan; Christina N Mazcko; Aswini Cherukuri; Erika P Berger; William C Kisseberth; Megan E Brown; Susan E Lana; Kristen Weishaar; Brian K Flesner; Jeffrey N Bryan; David M Vail; Jenna H Burton; Jennifer L Willcox; Anthony J Mutsaers; J Paul Woods; Nicole C Northrup; Corey Saba; Kaitlin M Curran; Haley Leeper; Heather Wilson-Robles; Brandan G Wustefeld-Janssens; Stephanie Lindley; Annette N Smith; Nikolaos Dervisis; Shawna Klahn; Mary Lynn Higginbotham; Raelene M Wouda; Erika Krick; Jennifer A Mahoney; Cheryl A London; Lisa G Barber; Cheryl E Balkman; Angela L McCleary-Wheeler; Steven E Suter; Olya Martin; Antonella Borgatti; Kristine Burgess; Michael O Childress; Janean L Fidel; Sara D Allstadt; Daniel L Gustafson; Laura E Selmic; Chand Khanna Journal: Clin Cancer Res Date: 2021-03-22 Impact factor: 13.801
Authors: Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens Journal: Leukemia Date: 2019-01-30 Impact factor: 11.528